Resveratrol inhibits nonalcoholic fatty liver disease in rats

Resveratrol inhibits nonalcoholic fatty liver disease in rats

<p>Abstract</p> <p>Background</p> <p>The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was...

Full description

Bibliographic Details
Main Authors:	Irastorza Belen, Cosme Angel, Sarasqueta Cristina, Aldazabal Pablo, García-Urkia Nerea, Larzabal Mikel, Beraza Marta, Hijona Elizabeth, Bujanda Luis, González Alberto, Arenas Juan I
Format:	Article
Language:	English
Published:	BMC 2008-09-01
Series:	BMC Gastroenterology
Online Access:	http://www.biomedcentral.com/1471-230X/8/40

Similar Items

Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
by: Hijona Elizabeth, et al.
Published: (2012-02-01)

Development of resveratrol with thiolated alginate as a supplement to prevent nonalcoholic fatty liver disease (NAFLD)
by: Yong-Chen Ke, et al.
Published: (2022-03-01)

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses
by: Xuan He, et al.
Published: (2023-09-01)

Nutritional Genomics in Nonalcoholic Fatty Liver Disease
by: Carolina Vasconcellos, et al.
Published: (2023-01-01)

Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Magdalena Mazurek, et al.
Published: (2023-02-01)

Nonalcoholic Fatty Liver Disease and Ayurveda
by: Sanjeev Sharma, et al.
Published: (2023-01-01)

History of Nonalcoholic Fatty Liver Disease
by: Amedeo Lonardo, et al.
Published: (2020-08-01)

Patophysiology of nonalcoholic fatty liver disease
by: Ewa Krzewicka-Romaniuk, et al.
Published: (2019-09-01)

Patophysiology of nonalcoholic fatty liver disease
by: Ewa Krzewicka-Romaniuk, et al.
Published: (2019-09-01)

The genetics of nonalcoholic fatty liver disease
by: Christoph H. Österreicher;, et al.
Published: (2007-04-01)

Treatment of nonalcoholic fatty liver disease
by: Paul Angulo, MD
Published: (2002-01-01)

Leptin in nonalcoholic fatty liver disease
by: Billur Canbakan, et al.
Published: (2008-07-01)

Effects of Aerobic Exercise and Resveratrol Supplementation on Plasma Level and Liver Expression of Activin A and Follistatin in a Rats with Nonalcoholic Fatty liver Disease
by: alireza barari, et al.
Published: (2020-03-01)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
by: Waseem Amjad, et al.
Published: (2023-08-01)

Synergistic delivery of resveratrol and ultrasmall copper-based nanoparticles by aptamer-functionalized ultrasound nanobubbles for the treatment of nonalcoholic fatty liver disease
by: Xinmin Guo, et al.
Published: (2022-09-01)

Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
by: Sebastião M.B. Duarte, et al.
Published: (2019-05-01)

Nonalcoholic fatty liver disease and non-liver comorbidities
by: Richie Manikat, et al.
Published: (2023-02-01)

Nonalcoholic fatty liver disease stratification by liver lipidomics
by: Olga Vvedenskaya, et al.
Published: (2021-01-01)

Diagnosis of Whipple's disease using molecular biology techniques Diagnóstico de la enfermedad de Whipple por técnicas de biología molecular. Aportación de dos casos
by: Ángel Cosme, et al.
Published: (2011-04-01)

Effects of resveratrol, exercises and their combination on Farnesoid X receptor, Liver X receptor and Sirtuin 1 gene expression and apoptosis in the liver of elderly rats with nonalcoholic fatty liver
by: Amir Hajighasem, et al.
Published: (2018-09-01)

Fatty liver in a child: Looking beyond nonalcoholic fatty liver disease
by: Jaya Agarwal, et al.
Published: (2021-01-01)

Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease
by: Wang Xin, et al.
Published: (2011-12-01)

Nonalcoholic fatty liver disease in children and adolescents
by: Hae Sang Lee
Published: (2024-02-01)

Combination Therapies for Nonalcoholic Fatty Liver Disease
by: Evangelia S. Makri, et al.
Published: (2022-07-01)

DNA Methylation in Nonalcoholic Fatty Liver Disease
by: Jeongeun Hyun, et al.
Published: (2020-10-01)

The Role of Phytosterols in Nonalcoholic Fatty Liver Disease
by: Otilia Frasinariu, et al.
Published: (2022-05-01)

Macrophage metabolism in nonalcoholic fatty liver disease
by: Wenhui Zhang, et al.
Published: (2023-10-01)

Editorial: Metabolism in nonalcoholic fatty liver disease
by: Sonia Michael Najjar, et al.
Published: (2023-08-01)

Implications of comorbidities in nonalcoholic fatty liver disease
by: Sherlot Juan Song, et al.
Published: (2023-04-01)

Risk factors in nonalcoholic fatty liver disease
by: Eunji Ko, et al.
Published: (2023-02-01)

Lean nonalcoholic fatty liver disease and sarcopenia
by: Milian Chen, et al.
Published: (2023-06-01)

Gut microbiota and nonalcoholic fatty liver disease
by: Boyeon Kim, et al.
Published: (2023-09-01)

Artificial intelligence in nonalcoholic fatty liver disease
by: Ali Mahzari
Published: (2022-12-01)

Noninvasive assessment of nonalcoholic fatty liver disease
by: Gajanan A Rodge, et al.
Published: (2021-01-01)

The role of complement in nonalcoholic fatty liver disease
by: Zhenya Guo, et al.
Published: (2022-09-01)

Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
by: Dae Ho Lee
Published: (2020-06-01)

Genetic predisposition in nonalcoholic fatty liver disease
by: Silvia Sookoian, et al.
Published: (2017-03-01)

Endothelial dysfunction in nonalcoholic fatty liver disease
by: Angela PELTEC, et al.
Published: (2022-01-01)

Nonalcoholic fatty liver disease – an etiological approach
by: Florentina Ioniță Radu, et al.
Published: (2014-06-01)

NRF-2 and nonalcoholic fatty liver disease
by: Arturo Solano-Urrusquieta, et al.
Published: (2020-09-01)